124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
11 clinical trials,   13 drugs   (DrugBank: 4 drugs),   3 drug target genes,   11 drug target pathways

Searched query = "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy", "CADASIL", "Autosomal dominant cerebral artery disease with subcortical infarct and leukoencephalopathy", "Autosomal dominant cerebral artery disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-001162-40-IT
(EUCTR)
05/04/200521/09/2005An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment.An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment. Donezepil HCl for treatment of patients with CADASIL (Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy) who have cognitive impairment.
MedDRA version: 6.1;Level: PT;Classification code 10009843
Trade Name: ARICEPT 5*28 CPR 5 MG
Product Name: NA
Product Code: NA
INN or Proposed INN: Donepezil
EISAI LTD UKNULLNot RecruitingFemale: yes
Male: yes
Finland;United Kingdom;Germany;Spain;Italy;Sweden
2EUCTR2004-001162-40-SE
(EUCTR)
01/04/200503/02/2005An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0;Level: PT;Classification code 10057678
Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
INN or Proposed INN: donepezil hydrochloride
Eisai LtdNULLNot RecruitingFemale: yes
Male: yes
150Finland;United Kingdom;Germany;Spain;Italy;Sweden
3EUCTR2004-001162-40-FI
(EUCTR)
08/03/200528/12/2004An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0;Level: PT;Classification code 10057678
Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
INN or Proposed INN: donepezil hydrochloride
Eisai LtdNULLNot RecruitingFemale: yes
Male: yes
150Phase 2Finland;Spain;Germany;Italy;United Kingdom;Sweden
4NCT00103948
(ClinicalTrials.gov)
February 200517/2/2005The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive ImpairmentAn 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive ImpairmentCognitive ImpairmentDrug: AriceptEisai LimitedNULLCompleted25 Years70 YearsBoth165Phase 2United States;Australia;Spain;Canada;Finland;France;Germany;Italy;Sweden;Switzerland;United Kingdom
5EUCTR2004-001162-40-DE
(EUCTR)
25/01/2005An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0;Level: PT;Classification code 10057678
Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
INN or Proposed INN: donepezil hydrochloride
Eisai LtdNULLNot RecruitingFemale: yes
Male: yes
150Finland;Spain;Germany;Italy;United Kingdom;Sweden